Key stats
About LEGAL & GENERAL UCITS ETF PLC - L&G PHARMA BREAKTHROUGH UCITS ETF
Home page
Inception date
Jan 23, 2018
Structure
Irish VCIC
Replication method
Physical
Dividend treatment
Capitalizes
Primary advisor
LGIM Managers (Europe) Ltd.
ISIN
IE00BF0H7608
The L&G Pharma Breakthrough UCITS ETF (the Fund) is an exchange traded fund (ETF) that aims to track the performance of the Solactive Pharma Breakthrough Value Index Net Total Return (the Index) subject to the deduction of the ongoing charges and other costs associated with operating the Fund.
Related funds
Classification
What's in the fund
Exposure type
Health Technology
Stock breakdown by region
Top 10 holdings
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
An exchange-traded fund (ETF) is a collection of assets (stocks, bonds, commodities, etc.) that track an underlying index and can be bought on an exchange like individual stocks.
ETLI assets under management is 13.46 M EUR. AUM is an important metric as it reflects the fund's size and can serve as a gauge of how successful the fund is in attracting investors, which, in its turn, can influence decision-making.
Since ETFs work like an individual stock, they can be bought and sold on exchanges (e.g. NASDAQ, NYSE, EURONEXT). As it happens with stocks, you need to select a brokerage to access trading. Explore our list of available brokers to find the one to help execute your strategies. Don't forget to do your research before getting to trading. Explore ETFs metrics in our ETF screener to find a reliable opportunity.
ETLI invests in stocks. See more details in our Analysis section.
ETLI expense ratio is 0.49%. It's an important metric for helping traders understand the fund's operating costs relative to assets and how expensive it would be to hold the fund.
No, ETLI isn't leveraged, meaning it doesn't use borrowings or financial derivatives to magnify the performance of the underlying assets or index it follows.
No, ETLI doesn't pay dividends to its holders.
ETLI shares are issued by Legal & General Group Plc
ETLI follows the Solactive Pharma Breakthrough Value Index. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
The fund started trading on Jan 23, 2018.
The fund's management style is passive, meaning it's aiming to replicate the performance of the underlying index by holding assets in the same proportions as the index. The goal is to match the index's returns.